PPG, Essilor in talks about Transitions Optical joint venture

Article

Discussions continue about what the future will hold for the Transitions Optical, the joint venture of Essilor International and PPG Industries.

 

Pittsburgh-PPG Industries Inc. continues discussions with Essilor International regarding the future of PPG’s and Essilor’s joint venture (JV), Transitions Optical. PPG is majority shareholder in Transitions Optical, holding a 51% interest in the JV companies. Essilor holds the remaining 49% interest and also is the largest customer of Transitions Optical.

PPG said it cannot predict the outcome of the discussions with Essilor regarding the future of Transitions Optical but believes that possible outcomes may include a modification of the current JV structure, a sale of all or a portion of PPG’s interests in Transitions Optical to Essilor, or a sale of all or a portion of Essilor’s interests in Transitions Optical to PPG.

PPG said it cannot predict the timing of the completion of its discussions with Essilor but expects that these talks are likely to continue over the next several months.

The two shareholders emphasized that their discussions will not impact the day-to-day operations of Transitions Optical. 

Recent Videos
Bonnie An Henderson in an interview for the EnVision Summit
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
© 2024 MJH Life Sciences

All rights reserved.